These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 723839)

  • 21. Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.
    Griswold DP; Corbett TH; Schabel FM
    Cancer Treat Rep; 1981; 65 Suppl 2():51-4. PubMed ID: 7346146
    [No Abstract]   [Full Text] [Related]  

  • 22. Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity.
    Mihich E
    Natl Cancer Inst Monogr; 1971 Dec; 34():90-102. PubMed ID: 4400958
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.
    Fefer A
    Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
    Bekesi JG; Roboz JP; Zimmerman E; Holland JF
    Cancer Res; 1976 Feb; 36(2 pt 2):631-9. PubMed ID: 1082796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
    Dosne Pasqualini C; Laguens RP
    Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of macrophages in tumour immunity. II. Involvement of a macrophage cytophilic factor during syngeneic tumour growth inhibition.
    Evans R; Alexander P
    Immunology; 1972 Oct; 23(4):627-36. PubMed ID: 4563478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential of lymphokines in the treatment of cancer.
    Hamblin AS; Wolstencroft RA; Dumonde DC; Hollander FD; Schuurs AH; Backhouse BM; O'Connell D; Paradinas F
    Dev Biol Stand; 1977 Apr 13-15; 38():335-41. PubMed ID: 608521
    [No Abstract]   [Full Text] [Related]  

  • 29. The combined effect of drugs and tumor-specific antibodies in protection against a mouse lymphoma.
    Davies DA
    Cancer Res; 1974 Nov; 34(11):3040-3. PubMed ID: 4418406
    [No Abstract]   [Full Text] [Related]  

  • 30. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody to dihydrofolate reductase from a methotrexate-resistant subline of the L1210 lymphoma.
    Perkins JP; Hillman G; Fischer D; Bertino JR
    Mol Pharmacol; 1969 May; 5(3):213-8. PubMed ID: 4389029
    [No Abstract]   [Full Text] [Related]  

  • 32. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytophilic antibody as an auxiliary factor in cell-mediated immunity.
    Ptak W
    Allerg Immunol (Leipz); 1973; 19(2-4):290-6. PubMed ID: 4375939
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
    Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibodies as carriers of anticancer agents.
    Rubens RD
    Lancet; 1974 Mar; 1(7856):498-9. PubMed ID: 4131895
    [No Abstract]   [Full Text] [Related]  

  • 37. Protocol design for lymphokine testing in clinical studies of human cancer.
    Lotze MT; Rosenberg SA
    Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
    Hamaoka T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tumor immunology].
    Milas L; Silobrcić V
    Lijec Vjesn; 1970; 92(1):5-33. PubMed ID: 4932237
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.